Clear Creek Bio doses first patient in Covid-19 trial with brequinar

Clear Creek Bio doses first patient in Covid-19 trial with brequinar

Source: 
Pharmaceutical Business Review
snippet: 


Clear Creek Bio has dosed the first patient in phase 1 clinical study of brequinar in hospitalised patients with Covid-19. 

The company has secured clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application of brequinar to treat Covid-19.

Brequinar is an orally available, potent, and selective small-molecule DHODH inhibitor, which can inhibit host cell de novo pyrimidine biosynthesis that is crucial for DNA and RNA synthesis.